Blooming Potential: BlossomHill Secures $100M Series B Funding for Small Molecule Cancer & Autoimmune Treatments

– BlossomHill Therapeutics, a biotech focusing on small-molecule drug design, has raised $100 million in a Series B financing round. – Led by Colt Ventures, the funding includes investors such as OrbiMed, Cormorant Asset Management, Vivo Capital, Hercules BioVentures Partners, and others. – Total capital raised by BlossomHill reaches $173 million after this round. – […]